These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9416653)

  • 61. [Effect of patient education on neuroleptic treatment of young psychotic patients].
    Goulet J; Lalonde P; Lavoie G; Jodoin F
    Can J Psychiatry; 1993 Oct; 38(8):571-3. PubMed ID: 7902200
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Measuring patient quality of life: is the health utility index useful?
    Tempier R; Pawliuk N
    Psychiatr Q; 2007 Mar; 78(1):53-62. PubMed ID: 17146727
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Paranoid/belligerence and neuroleptic dosage in newly admitted schizophrenic patients.
    Troisi A; Pasini A; de Angelis F; Spalletta G
    J Clin Psychopharmacol; 1997 Apr; 17(2):84-7. PubMed ID: 10950468
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Psychosocial changes in persistently psychotic schizophrenic patients after an 80% reduction of neuroleptic medication [corrected].
    DeLuca A; Pittman D; Gutierrez JM; Faraone SV
    J Psychosoc Nurs Ment Health Serv; 1988 Aug; 26(8):13-7. PubMed ID: 2903920
    [No Abstract]   [Full Text] [Related]  

  • 65. [The initial dysphoric reaction (IDR) to the first dose of neuroleptics].
    Schimmelmann BG; Schacht M; Perro C; Lambert M
    Nervenarzt; 2004 Jan; 75(1):36-43. PubMed ID: 14722660
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.
    Jolley AG; Hirsch SR; McRink A; Manchanda R
    BMJ; 1989 Apr; 298(6679):985-90. PubMed ID: 2567190
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia.
    McCormick L; Decker L; Nopoulos P; Ho BC; Andreasen N
    Schizophr Res; 2005 Dec; 80(1):73-84. PubMed ID: 16169191
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Neuropsychological test scores and clinical response to neuroleptic drugs in schizophrenic patients.
    Smith RC; Largen J; Vroulis G; Ravichandran GK
    Compr Psychiatry; 1992; 33(2):139-45. PubMed ID: 1347499
    [TBL] [Abstract][Full Text] [Related]  

  • 69. ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders.
    Noel JM;
    Am J Health Syst Pharm; 2007 Apr; 64(8):863-76. PubMed ID: 17420192
    [No Abstract]   [Full Text] [Related]  

  • 70. Wisconsin Card Sorting Test performance over time in schizophrenia. Preliminary evidence from clinical follow-up and neuroleptic reduction studies.
    Seidman LJ; Pepple JR; Faraone SV; Kremen WS; Cassens G; McCarley RW; Tsuang MT
    Schizophr Res; 1991 Oct; 5(3):233-42. PubMed ID: 1684721
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology.
    Gervin M; Browne S; Garavan J; Roe M; Larkin C; O'Callaghan E
    Eur Psychiatry; 1999 Nov; 14(7):405-9. PubMed ID: 10683626
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of anti-psychotic drugs.
    Mackay AV
    Br J Clin Pharmacol; 1981 Mar; 11(3):225-36. PubMed ID: 6111332
    [No Abstract]   [Full Text] [Related]  

  • 73. Instrumental evidence that age increases motor instability in neuroleptic-treated patients.
    Caligiuri MP; Lohr JB; Jeste DV
    J Gerontol; 1991 Sep; 46(5):B197-200. PubMed ID: 1679770
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Selection of neuroleptic dosage.
    Teicher MH; Baldessarini RJ
    Arch Gen Psychiatry; 1985 Jun; 42(6):636-7. PubMed ID: 2860885
    [No Abstract]   [Full Text] [Related]  

  • 75. A clinical trial of the effects of estrogen in acutely psychotic women.
    Kulkarni J; de Castella A; Smith D; Taffe J; Keks N; Copolov D
    Schizophr Res; 1996 Jul; 20(3):247-52. PubMed ID: 8827850
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Decreased urinary peptide excretion in schizophrenic patients after neuroleptic treatment.
    Reichelt KL; Teigland-Gjerstad B
    Psychiatry Res; 1995 Sep; 58(2):171-6. PubMed ID: 8570770
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Psychosis and behavioural symptoms of dementia: defining the role of neuroleptic interventions.
    Lawlor B; Bhriain SN
    Int J Geriatr Psychiatry; 2001 Dec; 16 Suppl 1():S2-6. PubMed ID: 11748783
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study.
    Berardi D; Amore M; Keck PE; Troia M; Dell'Atti M
    Biol Psychiatry; 1998 Oct; 44(8):748-54. PubMed ID: 9798079
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Remoxipride in the treatment of psychoses.
    Eriksson L
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 May; 18(3):619-23. PubMed ID: 8078994
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Extrapyramidal symptoms and oestrogen.
    Thompson KN; Kulkarni J; Sergejew AA
    Acta Psychiatr Scand; 2000 Feb; 101(2):130-4. PubMed ID: 10706013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.